CURIS INC (CRIS) Stock Fundamental Analysis

NASDAQ:CRIS • US2312693094

1.15 USD
+0.07 (+6.48%)
At close: Feb 13, 2026
1.14 USD
-0.01 (-0.87%)
After Hours: 2/13/2026, 8:01:06 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Taking everything into account, CRIS scores 2 out of 10 in our fundamental rating. CRIS was compared to 523 industry peers in the Biotechnology industry. CRIS may be in some trouble as it scores bad on both profitability and health. CRIS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • CRIS had negative earnings in the past year.
  • In the past year CRIS has reported a negative cash flow from operations.
  • CRIS had negative earnings in each of the past 5 years.
  • In the past 5 years CRIS always reported negative operating cash flow.
CRIS Yearly Net Income VS EBIT VS OCF VS FCFCRIS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • CRIS has a Return On Assets of -132.25%. This is amonst the worse of the industry: CRIS underperforms 81.26% of its industry peers.
Industry RankSector Rank
ROA -132.25%
ROE N/A
ROIC N/A
ROA(3y)-72.86%
ROA(5y)-52.24%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CRIS Yearly ROA, ROE, ROICCRIS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600

1.3 Margins

  • CRIS has a better Gross Margin (99.47%) than 98.66% of its industry peers.
  • In the last couple of years the Gross Margin of CRIS has remained more or less at the same level.
  • The Profit Margin and Operating Margin are not available for CRIS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 99.47%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.41%
GM growth 5Y0.85%
CRIS Yearly Profit, Operating, Gross MarginsCRIS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. Health

2.1 Basic Checks

  • CRIS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • CRIS has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, CRIS has more shares outstanding
  • There is no outstanding debt for CRIS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRIS Yearly Shares OutstandingCRIS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
CRIS Yearly Total Debt VS Total AssetsCRIS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • CRIS has an Altman-Z score of -67.90. This is a bad value and indicates that CRIS is not financially healthy and even has some risk of bankruptcy.
  • CRIS's Altman-Z score of -67.90 is on the low side compared to the rest of the industry. CRIS is outperformed by 91.97% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -67.9
ROIC/WACCN/A
WACC12.3%
CRIS Yearly LT Debt VS Equity VS FCFCRIS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 0.70 indicates that CRIS may have some problems paying its short term obligations.
  • CRIS has a worse Current ratio (0.70) than 88.34% of its industry peers.
  • CRIS has a Quick Ratio of 0.70. This is a bad value and indicates that CRIS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • CRIS has a worse Quick ratio (0.70) than 88.15% of its industry peers.
Industry RankSector Rank
Current Ratio 0.7
Quick Ratio 0.7
CRIS Yearly Current Assets VS Current LiabilitesCRIS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • CRIS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 53.01%, which is quite impressive.
  • Looking at the last year, CRIS shows a quite strong growth in Revenue. The Revenue has grown by 13.56% in the last year.
  • CRIS shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.75% yearly.
EPS 1Y (TTM)53.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%71.18%
Revenue 1Y (TTM)13.56%
Revenue growth 3Y0.8%
Revenue growth 5Y1.75%
Sales Q2Q%8.36%

3.2 Future

  • Based on estimates for the next years, CRIS will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.21% on average per year.
  • The Revenue is expected to grow by 57.54% on average over the next years. This is a very strong growth
EPS Next Y63.06%
EPS Next 2Y31.9%
EPS Next 3Y22.56%
EPS Next 5Y14.21%
Revenue Next Year17.66%
Revenue Next 2Y12.66%
Revenue Next 3Y28.44%
Revenue Next 5Y57.54%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CRIS Yearly Revenue VS EstimatesCRIS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 50M 100M 150M 200M
CRIS Yearly EPS VS EstimatesCRIS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -10 -20 -30 -40 -50

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CRIS. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRIS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRIS Price Earnings VS Forward Price EarningsCRIS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRIS Per share dataCRIS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

  • A more expensive valuation may be justified as CRIS's earnings are expected to grow with 22.56% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.9%
EPS Next 3Y22.56%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for CRIS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CURIS INC

NASDAQ:CRIS (2/13/2026, 8:01:06 PM)

After market: 1.14 -0.01 (-0.87%)

1.15

+0.07 (+6.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)03-30
Inst Owners35.77%
Inst Owner Change4.64%
Ins Owners6.98%
Ins Owner Change0%
Market Cap14.87M
Revenue(TTM)11.65M
Net Income(TTM)-36.56M
Analysts81.82
Price Target14.28 (1141.74%)
Short Float %5.07%
Short Ratio1.1
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.99%
Min EPS beat(2)16.89%
Max EPS beat(2)25.09%
EPS beat(4)3
Avg EPS beat(4)12.17%
Min EPS beat(4)-3.2%
Max EPS beat(4)25.09%
EPS beat(8)5
Avg EPS beat(8)-0.2%
EPS beat(12)8
Avg EPS beat(12)0.44%
EPS beat(16)9
Avg EPS beat(16)-0.26%
Revenue beat(2)2
Avg Revenue beat(2)5.5%
Min Revenue beat(2)2.12%
Max Revenue beat(2)8.88%
Revenue beat(4)3
Avg Revenue beat(4)15.4%
Min Revenue beat(4)-10.12%
Max Revenue beat(4)60.74%
Revenue beat(8)5
Avg Revenue beat(8)10.15%
Revenue beat(12)6
Avg Revenue beat(12)4.79%
Revenue beat(16)7
Avg Revenue beat(16)1.63%
PT rev (1m)0%
PT rev (3m)-3.45%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.43%
EPS NY rev (1m)0%
EPS NY rev (3m)1.85%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)5.14%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.32%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.28
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.67
EYN/A
EPS(NY)-1.83
Fwd EYN/A
FCF(TTM)-2.33
FCFYN/A
OCF(TTM)-2.33
OCFYN/A
SpS0.9
BVpS-1.14
TBVpS-1.83
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -132.25%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 99.47%
FCFM N/A
ROA(3y)-72.86%
ROA(5y)-52.24%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.41%
GM growth 5Y0.85%
F-Score4
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.7
Quick Ratio 0.7
Altman-Z -67.9
F-Score4
WACC12.3%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%71.18%
EPS Next Y63.06%
EPS Next 2Y31.9%
EPS Next 3Y22.56%
EPS Next 5Y14.21%
Revenue 1Y (TTM)13.56%
Revenue growth 3Y0.8%
Revenue growth 5Y1.75%
Sales Q2Q%8.36%
Revenue Next Year17.66%
Revenue Next 2Y12.66%
Revenue Next 3Y28.44%
Revenue Next 5Y57.54%
EBIT growth 1Y28.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.88%
EBIT Next 3Y-18.99%
EBIT Next 5Y1.48%
FCF growth 1Y25.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y25.74%
OCF growth 3YN/A
OCF growth 5YN/A

CURIS INC / CRIS FAQ

What is the fundamental rating for CRIS stock?

ChartMill assigns a fundamental rating of 2 / 10 to CRIS.


What is the valuation status of CURIS INC (CRIS) stock?

ChartMill assigns a valuation rating of 1 / 10 to CURIS INC (CRIS). This can be considered as Overvalued.


How profitable is CURIS INC (CRIS) stock?

CURIS INC (CRIS) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for CRIS stock?

The Earnings per Share (EPS) of CURIS INC (CRIS) is expected to grow by 63.06% in the next year.